From: Clinical and serological evaluation of a novel CENP-A peptide based ELISA
n = 99#, kappa = 0.73 | IIF | ||
CENP-A ELISA | pos (%) | neg (%) | Total |
pos (%) | 19 (19.2) | 6 (6.1) | 25 (25.3) |
neg (%) | 4 (4.0) | 70 (70.7) | 74 (74.8) |
Total | 23 (23.2) | 76 (76.8) | 99 (100.0) |
n = 265*, kappa = 0.86§ | CENP-A ELISA | ||
CENP-B ELISA | pos (%) | neg (%) | Total |
neg (%) | 4 (1.5) | 205 (77.4) | 209 (78.9) |
Total | 52 (19.6) | 213 (80.4) | 265 (100.0) |
n = 100#, kappa = 0.81§ | LIA (CENP-B) | ||
CENP-A ELISA | pos (%) | neg (%) | Total |
pos (%) | 20 (20.0) | 5 (5.0) | 25 (25.0) |
neg (%) | 2 (2.0) | 73 (73.0) | 75 (75.0) |
Total | 22 (22.0) | 78 (78.0) | 100 (100.0) |
n = 100#, kappa = 0.88§ | IIF | ||
LIA CENP-B | pos (%) | neg (%) | Total |
pos (%) | 19 (19.0) | 3 (3.0) | 22 (22.0) |
neg (%) | 1 (1.0) | 77 (77.0) | 78 (78.0) |
Total | 20 (20.0) | 80.0 | 100 (100.0) |
n = 82#, kappa = 0.97§ | EliA ® CENP-B | ||
CENP-A ELISA | pos (%) | neg (%) | Total |
pos (%) | 32 (39.0) | 1 (1.2) | 33 (40.2) |
neg (%) | 0 (0.0) | 49 (59.8) | 78 (59.8) |
Total | 32 (39.0) | 50 (61.0) | 100 (100.0) |